- Home
- CLLS vs INBX Comparison
CLLS vs INBX Comparison
Compare CLLS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLLS | INBX |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.4M | 1.5B |
| IPO Year | 2014 | 2024 |
Fundamental Metrics
Financial Performance| Metric | CLLS | INBX |
|---|---|---|
| Price | $1.42 | $98.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $5.33 | ★ $266.67 |
| AVG Volume (30 Days) | 171.9K | ★ 282.4K |
| Earning Date | 11-06-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.70 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $1.25 | $28.16 |
| 52 Week High | $5.48 | $155.29 |
Technical Indicators
Market Signals| Indicator | CLLS | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 26.03 | 43.08 |
| Support Level | $1.31 | $96.60 |
| Resistance Level | $3.47 | $106.40 |
| Average True Range (ATR) | 0.14 | 5.75 |
| MACD | -0.01 | -1.44 |
| Stochastic Oscillator | 17.81 | 11.13 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.